Cellebrite DI Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CLBT in the last 7 days.
Cellebrite DI Ltd (NASDAQ: CLBT) plans a corporate reorganization under a new U.S.-based parent company, pending approvals, to streamline operations and unlock shareholder value. GF Value™ estimates CLBT is 31.7% undervalued at $11.23 vs. an intrinsic value of $16.44. The company has a GF Score™ of 81/100, indicating strong fundamentals, but insiders have sold $5.2 million in shares over the past year.
Cellebrite DI Ltd. (CLBT) named CTO Chris Wade to lead Cellebrite Labs, focusing on mobile access, extraction, and decoding research. The move follows the Corellium acquisition, aiming to streamline R&D efforts.
Cellebrite (CLBT) plans to redomicile in the U.S. by mid-2027, pending approvals. The move aims to boost growth in key markets and attract more investors. CEO Shiv Ramji cited strategic benefits, including inclusion in key indices. Details will be shared in SEC filings.
Recent CLBT coverage spans technology, corporate actions and regulation.
In the last 30 days, CLBT insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($335K). The most active reporter was GEE DAVID NICHOLAS, Chief Marketing Officer, with 1 filing. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
Reorganization risk and timeline uncertainty could drive valuation volatility, while a U.S. parent structure may improve capital-market access if approvals proceed.
Organizational shift may accelerate R&D output and product releases.
The redomiciling could broaden the investor base and improve index inclusion, potentially supporting the share price.
The IRAP validation may unlock new government contracts and boost demand for the cloud evidence platform, while the C TEK kit expands the addressable defense market.
The clearances may improve market perception of Cellebrite's defense offerings but no immediate price catalyst is evident.
AlphAI scores every news story that mentions CLBT with an AI model for sentiment and relevance, and aggregates insider trades from Cellebrite DI Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cellebrite DI Ltd (NASDAQ: CLBT) plans a corporate reorganization under a new U.S.-based parent company, pending approvals, to streamline operations and unlock shareholder value. GF Value™ estimates CLBT is 31.7% undervalued at $11.23 vs. an intrinsic value of $16.44. The company has a GF Score™ of 81/100, indicating strong fundamentals, but insiders have sold $5.2 million in shares over the past year.
4 min readCellebrite DI Ltd. (CLBT) named CTO Chris Wade to lead Cellebrite Labs, focusing on mobile access, extraction, and decoding research. The move follows the Corellium acquisition, aiming to streamline R&D efforts.
1 min readCellebrite (CLBT) plans to redomicile in the U.S. by mid-2027, pending approvals. The move aims to boost growth in key markets and attract more investors. CEO Shiv Ramji cited strategic benefits, including inclusion in key indices. Details will be shared in SEC filings.
2 min readCellebrite DI (CLBT) announced its Guardian cloud platform received a PROTECTED-level IRAP assessment for Australian public sector use, and launched the C TEK backpack kit for military forensics. These developments could impact contract structures, deployment costs, and long-term demand from government clients. The company projects $787.4M revenue and $122.0M earnings by 2029, implying 15.3% yearly revenue growth. Analysts' fair value estimates range from $12.50 to $15.36, with the current share
2 min readCellebrite DI (CLBT) has seen its stock decline 28.48% in the past month and 35.82% year-to-date, despite a 3-year return of 45.30%. The company recently announced two product updates: Guardian platform cleared an Australian IRAP PROTECTED assessment, and the new C TEK field kit expands its defense offerings. Analysts debate its valuation, with a fair value estimate of $15.36 compared to its last close at $11.45, while its P/E ratio of 49.3x raises concerns about potential overvaluation.
3 min readCellebrite DI Ltd. (CLBT) announced that its cloud-based digital evidence management platform, Guardian, has achieved a PROTECTED classification level under the Infosec Registered Assessors Program (IRAP) in Australia. This milestone allows Australian government agencies to use Guardian for secure digital evidence collaboration. The assessment was conducted by CyberCX, an Australian Signals Directorate-endorsed IRAP assessor.
1 min readCellebrite DI Ltd (CLBT) announced its subsidiary achieved CMMC Level 2 certification. GF Value™ estimates CLBT is 26.6% undervalued at $12.01 vs. $16.36 intrinsic value. CLBT has a GF Score™ of 87, strong financials, and 11.2% 3-year revenue growth. Insiders sold $5.2M shares, while 5 gurus hold positions.
2 min readCellebrite (CLBT) announced its subsidiary, Cellebrite Federal Solutions (CFSI), achieved CMMC Level 2 cybersecurity certification, a DoW standard for handling Controlled Unclassified Information. CFSI implemented 110 security practices across 14 control families, according to the company. This certification and recent FedRAMP High authorization position CFSI as a trusted partner for federal agencies.
2 min readCellebrite's subsidiary, Cellebrite Federal Solutions (CFSI), achieved CMMC Level 2 certification, implementing 110 security practices. This early certification, verified by a third party, places CFSI among the top 3% of organizations meeting the Department of War standard, supporting its work with U.S. federal agencies.
2 min readCellebrite DI (CLBT) said it launched its rugged C-TEK kit for real-time mobile forensics and expanded its AI Genesis investigation platform to more global public sector and enterprise customers in August 2026. The article cites 2029 forecasts of $787.4M revenue and $122.0M earnings.
6 min read
